Charles Schwab
SLGC

Charles Schwab’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Charles Schwab’s Portfolio SLGC Stock Details SLGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,219,760
Closed -$3.09M – 3564
2023
Q4 		$3.09M Sell
1,219,760
-3,009
-0.2% -$7.01K ﹤0.01% 2501
2023
Q3 		$2.92M Buy
1,222,769
+62,116
+5% +$138K ﹤0.01% 2477
2023
Q2 		$2.68M Buy
1,160,653
+33,947
+3% +$95.8K ﹤0.01% 2461
2023
Q1 		$2.87M Buy
1,126,706
+13,026
+1% +$37.3K ﹤0.01% 2422
2022
Q4 		$2.8M Buy
1,113,680
+29,124
+3% +$81.3K ﹤0.01% 2455
2022
Q3 		$3.15M Buy
1,084,556
+49,996
+5% +$210K ﹤0.01% 2442
2022
Q2 		$4.68M Buy
1,034,560
+315,853
+44% +$1.88M ﹤0.01% 2215
2022
Q1 		$5.76M Buy
718,707
+26,432
+4% +$233K ﹤0.01% 2212
2021
Q4 		$8.06M Buy
+692,275
New +$8.29M ﹤0.01% 2115

Charles Schwab's SLGC Position: Q1 2024 in Review

Charles Schwab sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 1,219,760 shares — an estimated $3.09M sold.

Charles Schwab first reported a position in SLGC in Q4 2021 and held it in 9 quarters. The position peaked at $8.06M in Q4 2021. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

  • Charles Schwab reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 1,219,760 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $3.09M.
  • Charles Schwab first reported a position in SomaLogic, Inc. Class A Common Stock in Q4 2021 and held it in 9 quarters.
  • Charles Schwab's SomaLogic, Inc. Class A Common Stock position peaked at $8.06M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.